Abstract: TH-PO502
Stanniocalcin-1 Inhibits ER Stress and Renal Fibrosis via an AMP-Activated Protein Kinase-Dependent Pathway in HK2 Cells
Session Information
- CKD: Clinical Trials and Tubulointerstitial Disorders
November 02, 2017 | Location: Hall H, Morial Convention Center
Abstract Time: 10:00 AM - 10:00 AM
Category: Chronic Kidney Disease (Non-Dialysis)
- 308 CKD: Mechanisms of Tubulointerstitial Fibrosis
Authors
- Yang, Eun mi, Chonnam National University Hospital, Gwangju, Korea (the Republic of)
- Bae, Eun Hui, Chonnam National University Hospital, Gwangju, Korea (the Republic of)
- Ma, Seong Kwon, Chonnam National University Hospital, Gwangju, Korea (the Republic of)
- Kim, Soo Wan, Chonnam National University Hospital, Gwangju, Korea (the Republic of)
Background
The role of endoplasmic reticulum (ER) stress in the development of renal disease is a relatively recently described, and has been suggested as a cause for the fibrotic remodeling. Therefore, modulation of ER stress could be one of the possible therapeutic approaches to renal fibrosis. Stanniocalcin-1 (STC-1) is a multifunctional glycoprotein with antioxidant and anti-inflammatory properties and regulates AMP-activated protein kinase (AMPK) activity in the kidney. Activation of AMPK may reduce ER stress. The present study aimed to investigate the effects of STC-1 in ER stress and renal fibrosis in human renal proximal tubular (HK-2) cells
Methods
HK2 cells pretreated with STC-1 (200 ng/ml) for 1 hours followed by treatment with TGF-β (10 ng/ml) for 16 hours. To determine whether effect of STC-1 mediated by AMPK activation, pharmacological inhibitor (compound C, 5 uM) pretreated with STC-1. The protein expression of ER stress markers and fibrosis markers was determined by semiquantitative immunoblotting. The level of reactive oxygen species (ROS) was determined by fluorescent microscopy immunofluorescence.
Results
TGF-β treatment induced upregulation of glucose-related protein (GRP)78 and C/EBP homologous protein (CHOP) and STC-1 pretreatment attenuated the rise in the GRP 79 and CHOP. TGF-β treatment also induced upregulation of fibronectin and alpha-smooth muscle actin (α-SMA) and STC-1 pretreatment attenuated the TGF-β induced upregulation of fibronectin and α-SMA. STC-1 pretreatment significantly blocked TGF-β induced downregulation of AMPK and decreased level of ROS via upregulate the uncoupling protein (UCP2). On the other hand, compound C pretreatment with STC-1 before TGF-β treatment abolished the activation of AMPK, diminished the upregulation of UCP2, and aggravated ER stress and fibrosis but did not affect STC-1 expression.
Conclusion
STC-1 Inhibits ER stress and renal fibrosis via an AMPK Pathway and STC-1 may be a therapeutic target through reducing ER stress and renal fibrosis.
Funding
- Government Support - Non-U.S.